{"nctId":"NCT01817959","briefTitle":"Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation","startDateStruct":{"date":"2012-10"},"conditions":["Islet Transplantation in Diabetes Mellitus Type 1"],"count":51,"armGroups":[{"label":"Reparixin group","type":"EXPERIMENTAL","interventionNames":["Drug: Reparixin"]},{"label":"Placebo group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Reparixin","otherNames":["REP"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ages 18-70 years, inclusive.\n* Patients eligible for a pancreatic islet transplantation program\n* Planned intrahepatic islet transplantation alone from a non-living donor with brain death.\n* Patients willing and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations.\n* Patients who have given written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.\n\nExclusion Criteria:\n\n* Recipients of any previous transplant, including recipients of previous pancreatic islet transplantation.\n* Recipients of islet from a non-heart beating donor.\n* Pre-transplant average daily insulin requirement \\>1 IU/kg/day.\n* Pre-transplant (the more recent value obtained within the 4 months prior to enrolment) HbA1c \\>11%.\n* Patients with inadequate renal reserve as per calculated creatinine clearance (CLcr) \\< 60 mL/min according to the Cockcroft-Gault formula (1976).\n* Patients with hepatic dysfunction as defined by increased ALT (alanine aminotranferase) / AST (aspartate aminotransferase) \\> 3 x upper limit of normal (ULN) and increased total bilirubin \\> 3mg/dL \\[\\>51.3 µmol/L\\]).\n* Patients who receive treatment for a medical condition requiring chronic use of systemic steroids.\n* Treatment with any anti-diabetic medication other than insulin within 4 weeks of transplant.\n* Use of any investigational agent within 12 weeks of enrolment, including \"anti-inflammatory\" strategies (e.g. anti-TNFα, anti-IL-1 RA).\n* Hypersensitivity to:\n\n  1. ibuprofen or to more than one non steroidal anti-inflammatory drug (NSAID).\n  2. medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.\n* Pregnant or breast-feeding women; unwillingness to use effective contraceptive measures (females and males).\n\nAdditional exclusion criteria specific for US centre.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Curve (AUC) for the Serum C-peptide Level During the First 2 Hours of an MMTT (Mixed Meal Tolerance Test), Normalized by the Number of Islet Equivalent (IEQ)/kg","description":"The MMTT was to be performed ideally after an overnight fast. The test was to be initiated before 10 a.m. The Boost Original complete nutritional drink (Nestlé Nutrition) was used for the MMTT. Subjects were given 6 mL/kg of Boost preparation up to a maximum of 360 mL, to be drunk within 5 min. Blood samples for the C-peptide assay (the primary assessment) were withdrawn in fasting condition (basal), just prior to the meal (time 0, within 15 min prior to the meal) and then at 15, 30, 60, 90, 120 min after the meal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.247","spread":"0.218"},{"groupId":"OG001","value":"0.321","spread":"0.208"}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve (AUC) for the Serum C-peptide Level During the First 2 Hours of an MMTT (Mixed Meal Tolerance Test), Normalized by the Number of Islet Equivalent (IEQ)/kg","description":"The MMTT was to be performed ideally after an overnight fast. The test was to be initiated before 10 a.m. The Boost Original complete nutritional drink (Nestlé Nutrition) was used for the MMTT. Subjects were given 6 mL/kg of Boost preparation up to a maximum of 360 mL, to be drunk within 5 min. Blood samples for the C-peptide assay (the primary assessment) were withdrawn in fasting condition (basal), just prior to the meal (time 0, within 15 min prior to the meal) and then at 15, 30, 60, 90, 120 min after the meal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.234","spread":"0.243"},{"groupId":"OG001","value":"0.207","spread":"0.127"}]}]}]},{"type":"SECONDARY","title":"Percentage of Insulin-independent Patients at Day 75","description":"For the purpose of this study, insulin-independence is defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycaemic control, as defined by:\n\n* a glycated hemoglobin (HbA1c) level of less than 7%;\n* a glucose level after an overnight fast not exceeding 140 mg/dL (7.8 mmol/L) more than three times a week (based on measuring capillary glucose level a minimum of 7 times in a 7 day period);\n* a glucose level not exceeding 2-hour postprandial levels of 180 mg/dL (10 mmol/L) more than four times a week (based on measuring capillary glucose level 14 times in a 7 day period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"53.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Insulin-independent Patients at Day 365","description":"For the purpose of this study, insulin-independence is defined as freedom from the need to take exogenous insulin for 14 or more consecutive days, with adequate glycaemic control, as defined by:\n\n* a glycated hemoglobin (HbA1c) level of less than 7%;\n* a glucose level after an overnight fast not exceeding 140 mg/dL (7.8 mmol/L) more than three times a week (based on measuring capillary glucose level a minimum of 7 times in a 7 day period);\n* a glucose level not exceeding 2-hour postprandial levels of 180 mg/dL (10 mmol/L) more than four times a week (based on measuring capillary glucose level 14 times in a 7 day period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null},{"groupId":"OG001","value":"31.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieve and Maintain an HbA1c <7.0% (or a Reduction in HbA1c > 2%) AND Are Free of Severe Hypoglycaemic Events After Transplant in the Efficacy Population 1","description":"For the purpose of this study, a severe hypoglycaemic event is defined as an event with one of the following symptoms: memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness or visual symptoms, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level \\<54mg/dL (3.0 mmol/L) or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Did Not Receive a 2nd Islet Infusion","description":"This endpoint describes subjects who were not allocated to a 2nd islet infusion because they were insulin independent after the 1st islet infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of Severe Hypoglycaemic Events in the Efficacy Population 1","description":"The cumulative number of severe hypoglycaemic events after last transplant was assessed. For the purpose of this study, a severe hypoglycaemic event is defined as an event with one of the following symptoms: memory loss, confusion, uncontrollable behaviour, irrational behaviour, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness or visual symptoms, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level \\<54 mg/dL (3.0 mmol/L) or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","spread":"8.23"},{"groupId":"OG001","value":"3.50","spread":"7.65"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Average Daily Insulin Requirements in Efficacy Population 1","description":"Change from baseline is assessed as absolute decrease from pre-transplant levels. For the purpose of this study, daily insulin is averaged over the previous week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.231","spread":"0.204"},{"groupId":"OG001","value":"-0.220","spread":"0.203"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.389","spread":"0.163"},{"groupId":"OG001","value":"-0.463","spread":"0.168"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.302","spread":"0.167"},{"groupId":"OG001","value":"-0.375","spread":"0.208"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Average Daily Insulin Requirements in Efficacy Population 1","description":"Change from baseline is assessed as percentage decrease from pre-transplant levels. For the purpose of this study, daily insulin is averaged over the previous week.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.5","spread":"54.1"},{"groupId":"OG001","value":"-35.0","spread":"35.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-74.0","spread":"28.6"},{"groupId":"OG001","value":"-27.7","spread":"26.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.4","spread":"35.8"},{"groupId":"OG001","value":"-63.7","spread":"33.7"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in HbA1c % From Pre-transplant Levels in Efficacy Population 1","description":"Change from baseline in Glycated haemoglobin (HbA1c) was assessed as absolute decrease from pre-transplant levels. Diagnostic standards for HbA1c from American Diabetes Association are: \\<5.7% Normal; 5.7-6.4% prediabetes; \\>6.5 diabetes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.58","spread":"0.87"},{"groupId":"OG001","value":"-2.18","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"1.10"},{"groupId":"OG001","value":"-2.81","spread":"1.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.30","spread":"1.14"},{"groupId":"OG001","value":"-1.87","spread":"1.26"}]}]}]},{"type":"SECONDARY","title":"Percent Change in HbA1c % From Pre-transplant Levels in Efficacy Population 1","description":"Change from baseline in Glycated haemoglobin (HbA1c) was assessed as percentage decrease from pre-transplant levels. Diagnostic standards for HbA1c from American Diabetes Association are: \\<5.7% Normal; 5.7-6.4% prediabetes; \\>6.5 diabetes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.9","spread":"9.5"},{"groupId":"OG001","value":"-24.0","spread":"10.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.4","spread":"11.6"},{"groupId":"OG001","value":"-30.5","spread":"11.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.7","spread":"13.1"},{"groupId":"OG001","value":"-20.9","spread":"12.9"}]}]}]},{"type":"SECONDARY","title":"Basal (Fasting) and 0 to 120 Min Time Course of Glucose Derived From the Mixed Meal Tolerance Test (MMTT) in Efficacy Population 1","description":"Glucose levels were measured at the baseline in fasting condition, and at the following timepoints: 15, 30, 60, 90, 120 min after mixed meal at the hereunder reported time frame.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.6","spread":"51.7"},{"groupId":"OG001","value":"118.9","spread":"40.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146.0","spread":"56.0"},{"groupId":"OG001","value":"132.5","spread":"27.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191.6","spread":"66.6"},{"groupId":"OG001","value":"168.1","spread":"50.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"236.9","spread":"86.0"},{"groupId":"OG001","value":"219.1","spread":"65.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"254.0","spread":"110.1"},{"groupId":"OG001","value":"245.0","spread":"84.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"264.1","spread":"116.7"},{"groupId":"OG001","value":"246.0","spread":"84.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.8","spread":"19.8"},{"groupId":"OG001","value":"112.8","spread":"18.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130.0","spread":"22.3"},{"groupId":"OG001","value":"134.8","spread":"26.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166.7","spread":"33.6"},{"groupId":"OG001","value":"157.8","spread":"32.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189.1","spread":"57.9"},{"groupId":"OG001","value":"172.0","spread":"70.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191.8","spread":"72.8"},{"groupId":"OG001","value":"175.1","spread":"99.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188.0","spread":"88.1"},{"groupId":"OG001","value":"171.7","spread":"104.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.2","spread":"37.6"},{"groupId":"OG001","value":"125.1","spread":"64.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.5","spread":"43.1"},{"groupId":"OG001","value":"146.7","spread":"68.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180.1","spread":"53.9"},{"groupId":"OG001","value":"182.7","spread":"80.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"221.2","spread":"81.2"},{"groupId":"OG001","value":"213.6","spread":"106.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"235.7","spread":"112.6"},{"groupId":"OG001","value":"222.0","spread":"122.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239.9","spread":"127.6"},{"groupId":"OG001","value":"205.5","spread":"104.3"}]}]}]},{"type":"SECONDARY","title":"Basal (Fasting) and 0 to 120 Min Time Course of C-peptide (Non-normalized) Derived From the MMTT in Efficacy Population 1","description":"C-peptide levels not normalized by the number of islet equivalent (IEQ)/kg were measured at the baseline in fasting condition, and at the following timepoints: 15, 30, 60, 90, 120 min after mixed meal at the hereunder reported time frame.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.46"},{"groupId":"OG001","value":"0.51","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.77"},{"groupId":"OG001","value":"0.67","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":"1.32"},{"groupId":"OG001","value":"0.89","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"1.80"},{"groupId":"OG001","value":"1.46","spread":"1.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"1.64"},{"groupId":"OG001","value":"1.80","spread":"1.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"1.34"},{"groupId":"OG001","value":"2.04","spread":"1.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"0.69"},{"groupId":"OG001","value":"1.27","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":"1.36"},{"groupId":"OG001","value":"1.73","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"1.90"},{"groupId":"OG001","value":"2.55","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":"2.15"},{"groupId":"OG001","value":"3.65","spread":"2.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.30","spread":"2.15"},{"groupId":"OG001","value":"3.56","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":"1.98"},{"groupId":"OG001","value":"2.90","spread":"1.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.65"},{"groupId":"OG001","value":"1.14","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"1.02"},{"groupId":"OG001","value":"1.32","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":"1.66"},{"groupId":"OG001","value":"2.17","spread":"1.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":"2.38"},{"groupId":"OG001","value":"2.88","spread":"181"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"2.27"},{"groupId":"OG001","value":"3.13","spread":"1.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":"1.74"},{"groupId":"OG001","value":"3.12","spread":"1.68"}]}]}]},{"type":"SECONDARY","title":"Basal (Fasting) and 0 to 120 Min Time Course of Insulin Derived From the MMTT in Efficacy Population 1","description":"Insulin levels were measured at the baseline in fasting condition, and at the following timepoints: 15, 30, 60, 90, 120 min after mixed meal at the hereunder reported time frame.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":"43.6"},{"groupId":"OG001","value":"15.2","spread":"39.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"16.6"},{"groupId":"OG001","value":"11.8","spread":"13.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":"27.7"},{"groupId":"OG001","value":"15.8","spread":"16.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":"32.9"},{"groupId":"OG001","value":"23.0","spread":"24.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":"27.4"},{"groupId":"OG001","value":"22.3","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":"28.2"},{"groupId":"OG001","value":"23.1","spread":"18.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"10.3"},{"groupId":"OG001","value":"9.0","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":"16.0"},{"groupId":"OG001","value":"17.5","spread":"12.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":"30.0"},{"groupId":"OG001","value":"31.1","spread":"17.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":"23.4"},{"groupId":"OG001","value":"37.8","spread":"20.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":"23.6"},{"groupId":"OG001","value":"31.2","spread":"20.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":"19.2"},{"groupId":"OG001","value":"25.3","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"7.6"},{"groupId":"OG001","value":"6.2","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"17.0"},{"groupId":"OG001","value":"10.8","spread":"9.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"19.2"},{"groupId":"OG001","value":"20.7","spread":"13.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.5","spread":"30.1"},{"groupId":"OG001","value":"25.6","spread":"14.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":"23.5"},{"groupId":"OG001","value":"26.1","spread":"17.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":"18.4"},{"groupId":"OG001","value":"27.1","spread":"11.8"}]}]}]},{"type":"SECONDARY","title":"β-cell Function as Assessed by β-score in Efficacy Population 1","description":"The β-score ranges from 0 (no graft function) to 8 (interpreted as an index of excellent graft function), and gives 0-2 points each for glucose, HbA1C, stimulated C-peptide and insulin requirement. Both for the total and partial scores the higher the score, the better the outcome.\n\nFasting plasma glucose (mg/dL): ≤99 (Score 2); 100 - 124 (Score 1); ≥125 (Score 0); HbA1c (%): ≤6.1(Score 2); 6.2 - 6.9 (Score 1); ≥ 7.0 (Score 0); Daily average (previous week) insulin (IU/kg/day): --- (Score 2); 0.01 - 0.24 (score 1); ≥ 0.25 (Score 0) Stimulated C-peptide (ng/mL): ≥ 0.9; 0.3 - 0.89; ≤0.3","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.19","spread":"2.37"},{"groupId":"OG001","value":"4.06","spread":"2.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.53","spread":"1.42"},{"groupId":"OG001","value":"5.67","spread":"2.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.63","spread":"2.50"},{"groupId":"OG001","value":"5.13","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"β-cell Function as Assessed by Transplant Estimated Function (TEF) in Efficacy Population 1","description":"TEF selects the two pivotal components of the β-score (DIR and A1C) and links them together through a simple description of how insulin supply influences the patient's glycemic control.\n\nTEF was evaluated by the following equation: TEF = a.DIR + b.HbA1c + c where DIR = daily insulin requirement (average in the previous week); a = -1; b = 1/-5.43; c = -a.DIR (pre-transplant) - b.HbA1c (pre-transplant)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.523","spread":"0.260"},{"groupId":"OG001","value":"0.621","spread":"0.332"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.764","spread":"0.240"},{"groupId":"OG001","value":"0.981","spread":"0.275"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.539","spread":"0.320"},{"groupId":"OG001","value":"0.719","spread":"0.359"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Frequency of Patients Positive/Negative for Autoantibodies Against Glutamic Acid Decarboxylase (GAD) in Efficacy Population 1","description":"Auto-antibodies were assayed on cell-free serum samples obtained as per centre practice ideally by immunoprecipitation of recombinant antigens. The Luminescent Immuno-Precipitation System based on chimeric autoantigens fused to luciferase enzyme was suggested as the preferred method to be used. Luciferase activity was measured in recovered immune-complex.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"52.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null},{"groupId":"OG001","value":"47.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":null},{"groupId":"OG001","value":"35.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Frequency of Patients Positive/Negative for Autoantibodies Against Islet Antigen-2 (IA-2) in Efficacy Population 1","description":"Auto-antibodies were assayed on cell-free serum samples obtained as per centre practice ideally by immunoprecipitation of recombinant antigens. The Luminescent Immuno-Precipitation System based on chimeric autoantigens fused to luciferase enzyme was suggested as the preferred method to be used. Luciferase activity was measured in recovered immune-complex.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Frequency of Patients Positive/Negative for Autoantibodies Against Class I Human Leucocyte Antigen (HLA) in Efficacy Population 1","description":"Anti-HLA antibodies were assayed on cell-free serum samples obtained as per centre practice ideally by the Luminex analyzer. Class I and II positive/negative results were recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"27.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null},{"groupId":"OG001","value":"72.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"23.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"76.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"31.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"68.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"26.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"26.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Frequency of Patients Positive/Negative for Autoantibodies Against Class II Human Leucocyte Antigen (HLA) in Efficacy Population 1","description":"Anti-HLA antibodies were assayed on cell-free serum samples obtained as per centre practice ideally by the Luminex analyzer. Class I and II positive/negative results were recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"93.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"93.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":29},"commonTop":["Nausea","Headache","Abdominal pain","Vomiting","Diarrhoea"]}}}